United Therapeutics Corporation (UTHR)

Market Cap	13.28B
Revenue (ttm)	2.99B
Net Income (ttm)	1.21B
Shares Out	45.11M
EPS (ttm)	25.10
PE Ratio	11.73
Forward PE	10.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	284,126
Open	295.66
Previous Close	295.22
Day's Range	291.13 - 298.30
52-Week Range	266.98 - 417.82
Beta	0.54
Analysts	Buy
Price Target	386.15 (+31.13%)
Earnings Date	Jul 30, 2025

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 17, 1999
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: UTHR
• Website: https://www.unither.com

Financial Performance

In 2024, United Therapeutics's revenue was $2.88 billion, an increase of 23.63% compared to the previous year's $2.33 billion. Earnings were $1.20 billion, an increase of 21.35%.

Analyst Summary

According to 13 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price target is $386.15, which is an increase of 31.13% from the latest price.

Price Target

$386.15

(31.13% upside)

Analyst Consensus: Buy